+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer



Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer



European Respiratory Journal 38(4): 903-910



The clinical applicability of screening surgically resected nonsmall cell lung cancer (NSCLC) tumour tissue and serum for activating epidermal growth factor receptor (EGFR) mutation is unknown. Furthermore, the comparative accuracy of inexpensive EGFR mutation tests, mutant-enriched (ME)-PCR and high-resolution melt (HRM) has not been determined. Lung tumour DNA from 522 surgically resected stage I-IV NSCLC and matched serum DNA from a subset of 64 subjects was analysed for EGFR mutations in exons 19 and 21 using ME-PCR and HRM. Additionally, 97 subjects had previous EGFR DNA sequencing data available for comparison. ME-PCR and HRM detected EGFR mutations in 5% (27 out of 522) of tumour samples. Compared to DNA sequencing, ME-PCR had a sensitivity of 100% and specificity of 99%, while HRM had 100% sensitivity and specificity. Six subjects with EGFR mutation tumours had matched serum, where ME-PCR detected mutations in three samples and HRM in two samples. In the cohort of never-smoker subjects, those with EGFR mutated tumours had worse survival compared with wild-type tumours (30 versus 49 months; p=0.017). ME-PCR and HRM have similar accuracy in detecting EGFR mutations but the prognostic implications of the mutations in resected NSCLC warrants further study.

(PDF emailed within 0-6 h: $19.90)

Accession: 036219850

Download citation: RISBibTeXText

PMID: 21349912

DOI: 10.1183/09031936.00190110


Related references

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Annals of Oncology 25(10): 1935-1940, 2015

Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations. Annals of Thoracic Surgery 101(2): 473-480, 2016

Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma. Annals of Surgical Oncology 25(4): 1069-1078, 2018

EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. International Journal of Molecular Sciences 14(12): 24549-24559, 2014

A case of different EGFR mutations in surgically resected synchronous triple lung cancer. Journal of Thoracic Disease 10(4): E255-E259, 2018

EGFR gene mutations: is it prognostic or predictive in surgically resected lung cancer?. Journal of Thoracic Oncology 7(12): 1739-1741, 2013

Imaging surveillance for surgically resected stage I nonsmall cell lung cancer: Is more always better?. The Journal of Thoracic and Cardiovascular Surgery 157(3): 1205-1217.e2, 2019

Raman microscopy in the diagnosis and prognosis of surgically resected nonsmall cell lung cancer. Journal of Biomedical Optics 15(2): 026015, 2010

Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer. International Journal of Cancer 130(2): 377-387, 2012

Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer. European Respiratory Journal 46(6): 1541-1543, 2016

P1.08-034 Prognostic Impact of Egfr Mutation in Patients with Surgically Resected Lung Adenocarcinoma; Analysis about Subtypes of Egfr Mutations. Journal of Thoracic Oncology 12(1): S751-S752, 2017

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis. Medicine 94(33): E1263, 2015

Bcl-2 oncoprotein in surgically resected nonsmall cell lung cancer: Possibly favorable prognostic factor in association with low incidence of distant metastasis. Journal of Surgical Oncology 64(1): 48-54, 1997

LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer. Translational Research 163(1): 27-35, 2014

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. Medicine 94(21): E775, 2015